Company Description
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada.
The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA.
The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015.
ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Country | CA |
| IPO Date | Jan 10, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Neil K. Warma M.B.A. |
Contact Details
Address: 1920 Yonge Street Toronto, ON CA | |
| Website | https://www.promisneurosciences.com |
Stock Details
| Ticker Symbol | PMN |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001374339 |
| CUSIP Number | 74346M406 |
| ISIN Number | CA74346M4065 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neil K. Warma M.B.A. | Chief Executive Officer, President & Director |
| Daniel E. Geffken M.B.A. | Chief Financial Officer |
| Gavin T. Malenfant | Chief Operating Officer |
| Dennis Chen Ph.D. | Head of Manufacturing & Senior Consultant |
| Dr. David Wishart Ph.D. | Chief Physics Officer |
| Dr. Ernest D. Bush Ph.D. | Head of Pharmacology/Toxicology & Senior Consultant |
| Dr. Johanne Kaplan Ph.D. | Chief Development Officer |
| Dr. Larry Douglas Altstiel M.D., Ph.D. | Chief Medical Officer |
| Dr. Neil R. Cashman M.D. | Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director |
| Eugene W. Williams | Co-Founder & Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Jan 08, 2025 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |